Merck and Ridgeback Biotherapeutics have announced the initiation of the Phase 3 MOVe-NOW clinical trial to evaluate LAGEVRIOTM (molnupiravir) for the treatment of COVID-19 in high-risk adults. The study aims to provide important insights into how LAGEVRIOTM can be used to help prevent severe outcomes in the current COVID-19 environment.

Merck is known as MSD outside of the United States and Canada. Ridgeback Biotherapeutics is involved in the development of LAGEVRIOTM.

Merck and Ridgeback Biotherapeutics Partner to Initiate Phase 3 Study for LAGEVRIOTM in Treating COVID-19 in High-Risk Adults

Merck and Ridgeback Biotherapeutics Partner to Initiate Phase 3 Study for LAGEVRIOTM in Treating COVID-19 in High-Risk Adults

Company Info